what I really like about the article is
" Prima BioMed expects to enrol 1,000 patients in the study, which will be conducted across 100 sites in countries around the world. "
... 2 points
1. A large statiscal sample to validate results ... beyond questioning
2. A large trial base and volume of 'recruits ' ... that will enable Prime to get the ' mechanics ' and " manufacturing ' processes right ... unlike DNDN ... and be ready to roll big time when Commercialisation goes full swing ....
prima biomed: time to change leader, page-9
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.8¢ |
Change
0.003(0.79%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.0¢ | 31.0¢ | $326.5K | 1.036M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 214028 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 131706 | 23 |
View Market Depth
| Last trade - 12.23pm 19/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |